Wang Lai 4

What Happened Wang Lai, President and Global Head of R&D at BeOne Medicines (ONC), received two restricted share unit (RSU) awards on June 11, 2026 totaling 348,400 shares (118,625 and 229,775), each recorded as acquisitions at $0.00. On the same date he disposed of 756 American Depositary Shares (ADSs) in an open-market sale at a weighted average price of $261.00, generating $197,318. The sale was effected to satisfy mandatory tax withholding tied to a vesting event.

Key Details

• Transaction date: June 11, 2026 (Form 4 filed June 15, 2026).
• Awards: 118,625 RSUs (F1) and 229,775 RSUs (F10); combined 348,400 RSUs granted at $0.00. One grant is reported as a derivative award.
• Sale: 756 ADSs sold; weighted average price $261.00 (range $260.87–$261.16 per F8); proceeds $197,318. Sale made pursuant to mandatory tax withholding (F7).
• Vesting: F1 — 25% vests each anniversary of June 11, 2026; F10 — 25% on first anniversary of June 11, 2026, then remaining shares vest in 36 equal monthly installments. Unvested RSUs may accelerate on certain termination events.
• ADS / ordinary share note: Each ADS represents 13 ordinary shares (F6).
• Shares owned after transaction: Not specified in the filing.
• Filing timeliness: No indication in this filing that it was late.

Context RSU awards are compensation grants that vest over time and do not require an immediate cash outlay by the executive; they are more of a retention/compensation signal than a direct market purchase. The small sale reported here was a routine, mandatory withholding sale to cover taxes on RSU vesting (not a discretionary stock sale for investment purposes). Additional footnotes (F2–F5) describe other holdings and an RMB-share employee participation plan in which the reporting person participated; those notes clarify indirect economic interests and conversion mechanics for Shanghai STAR Market shares.